# MMP9

## Overview
Matrix metallopeptidase 9 (MMP9) is a gene that encodes the enzyme matrix metallopeptidase 9, also known as gelatinase B, which is part of the matrix metalloproteinase (MMP) family. This enzyme is categorized as a protease and is involved in the degradation of extracellular matrix components, playing a crucial role in various physiological processes such as tissue remodeling, angiogenesis, and synaptic plasticity (Vafadari2016MMP‐9; Vandooren2013Biochemistry). MMP9 is characterized by its multi-domain structure, which includes a catalytic domain essential for its proteolytic activity, and a hemopexin domain that influences substrate specificity and inhibitor interactions (Swetha2018Biomolecular; Vandooren2013Biochemistry). The regulation of MMP9 activity is tightly controlled by tissue inhibitors of metalloproteinases (TIMPs), with TIMP-1 being a primary regulator (Charzewski2021Structural). Clinically, MMP9 is implicated in various pathological conditions, including cancer, where its overexpression is associated with tumor progression and metastasis, making it a potential target for therapeutic interventions (Xu2020Association; Cheng2022Landscape).

## Structure
Matrix metallopeptidase 9 (MMP-9) is a multi-domain enzyme with a complex molecular structure. The primary structure of MMP-9 includes a signal peptide, a propeptide, a catalytic domain, a Zn2+-binding domain, an O-glycosylated (OG) domain, and a hemopexin (PEX) domain (Swetha2018Biomolecular). The catalytic domain is characterized by a metal-binding site with a catalytically essential Glu402 and a Zn2+ ion, coordinated by three histidine residues (Rowsell2002Crystal). The secondary structure of the catalytic domain includes five beta-strands in a twisted beta-sheet layered against three helices (Elkins2002Structure).

The tertiary structure is stabilized by zinc and calcium ions, with the catalytic domain forming a slightly elongated globular shape (Swetha2018Biomolecular). The PEX domain, consisting of a four-bladed β-propeller structure, is crucial for substrate specificity and interactions with inhibitors (Vandooren2013Biochemistry).

MMP-9 can form homodimers and heterodimers, with dimerization facilitated by disulfide bonds in the PEX domain (Swetha2018Biomolecular). Post-translational modifications include glycosylation, with both N- and O-linked oligosaccharides contributing to the enzyme's size and shape (Van2002Biochemistry). The enzyme's structure is further complicated by its flexibility and heterogeneity, which pose challenges for crystallography (Vandooren2013Biochemistry).

## Function
Matrix metallopeptidase 9 (MMP-9) is an enzyme that plays a significant role in the breakdown of extracellular matrix (ECM) components, which is crucial for various physiological processes in healthy human cells. MMP-9 is involved in angiogenesis and vascular remodeling by cleaving ECM components and processing angiogenic chemokines and cytokines such as VEGF and FGF. It is essential for the induction of angiogenesis, as it triggers the release of bioactive FGF-2, which acts through its receptor FGFR-2 (Vandooren2013Biochemistry).

In the brain, MMP-9 is critical for synaptic plasticity, learning, and memory. It facilitates long-term potentiation (LTP) by causing dendritic spines to become longer and thinner, which is essential for synaptic changes. MMP-9 activity increases in response to neuronal activity, leading to the cleavage of b-dystroglycans, which is important for synaptic modifications (Vafadari2016MMP‐9; Vandooren2013Biochemistry).

MMP-9 is also involved in bone development and remodeling, particularly in maintaining trabecular bone architecture. It is highly expressed in osteoclasts and is necessary for their migration and differentiation, processes critical for bone resorption (Vandooren2013Biochemistry). In epithelial regeneration, MMP-9 expression is upregulated during wound healing, playing a complex role in re-epithelialization (Vandooren2013Biochemistry).

## Clinical Significance
Alterations in the expression of the MMP9 gene are significantly associated with various diseases, particularly cancer. In breast cancer, MMP9 is notably upregulated, correlating with tumor progression and poor prognosis. High levels of MMP9 expression are linked to shorter recurrence-free survival in breast cancer patients, suggesting its potential as a prognostic marker (Cheng2022Landscape). MMP9 is also involved in the infiltration of immune cells in breast cancer tissues, affecting tumor growth and metastasis (Cheng2022Landscape).

In uveal melanoma, MMP9 is upregulated and associated with shorter overall survival, indicating its role as a prognostic biomarker (Wang2021MMP1). MMP9's role extends to other cancers, such as melanoma, where its overexpression is linked to intragenic hypermethylation, contributing to tumor invasion and migration (Falzone2016MMP9).

MMP9 polymorphisms, such as the -1562C>T variant, are associated with increased cancer risk and metastasis, influencing gene expression and cancer susceptibility (Xu2020Association; Farina2014Gelatinase). These genetic variations highlight MMP9's clinical significance in cancer biology and its potential as a target for therapeutic interventions (Rashid2023Novel).

## Interactions
MMP9, or matrix metallopeptidase 9, is known for its interactions with tissue inhibitors of metalloproteinases (TIMPs), particularly TIMP-1 and TIMP-2. These interactions are crucial for regulating MMP9's enzymatic activity. TIMP-1 binds to MMP9 in a 1:1 ratio, forming both inhibitory and non-inhibitory complexes. The inhibitory complexes involve TIMP-1 binding to the catalytic domain of MMP9, while non-inhibitory complexes involve binding to the hemopexin domain (Olson2000Characterization; Charzewski2021Structural). 

MMP9 can exist in monomeric and dimeric forms, with TIMP-1 forming stable complexes with both forms. The dimeric form of MMP9 shows a slightly greater affinity for TIMP-1 compared to the monomeric form (Olson2000Characterization). TIMP-2, on the other hand, does not bind to pro-MMP9 but can bind to active MMP9 forms with lower affinity than TIMP-1 (Olson2000Characterization).

MMP9 also interacts with heat shock protein 90 (HSP90) in breast cancer cells. This interaction is essential for the activation of MMP9, as blocking HSP90 with a monoclonal antibody prevents MMP9 activation (Stellas2010Monoclonal). These interactions highlight the complex regulatory mechanisms controlling MMP9 activity and its role in various physiological and pathological processes.


## References


[1. (Swetha2018Biomolecular) Rayala Swetha, Chandrim Gayen, Devendra Kumar, Tryambak Deo Singh, Gyan Modi, and Sushil Kumar Singh. Biomolecular basis of matrix metallo proteinase-9 activity. Future Medicinal Chemistry, 10(9):1093–1112, April 2018. URL: http://dx.doi.org/10.4155/fmc-2017-0236, doi:10.4155/fmc-2017-0236. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.4155/fmc-2017-0236)

[2. (Falzone2016MMP9) Luca Falzone, Rossella Salemi, Salvatore Travali, Aurora Scalisi, James A. McCubrey, Saverio Candido, and Massimo Libra. Mmp-9 overexpression is associated with intragenic hypermethylation of mmp9 gene in melanoma. Aging, 8(5):933–944, April 2016. URL: http://dx.doi.org/10.18632/aging.100951, doi:10.18632/aging.100951. This article has 65 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.100951)

[3. (Van2002Biochemistry) Philippe E. Van den Steen, Bénédicte Dubois, Inge Nelissen, Pauline M. Rudd, Raymond A. Dwek, and Ghislain Opdenakker. Biochemistry and molecular biology of gelatinase b or matrix metalloproteinase-9 (mmp-9). Critical Reviews in Biochemistry and Molecular Biology, 37(6):375–536, January 2002. URL: http://dx.doi.org/10.1080/10409230290771546, doi:10.1080/10409230290771546. This article has 730 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/10409230290771546)

[4. (Charzewski2021Structural) Łukasz Charzewski, Krystiana A. Krzyśko, and Bogdan Lesyng. Structural characterisation of inhibitory and non-inhibitory mmp-9–timp-1 complexes and implications for regulatory mechanisms of mmp-9. Scientific Reports, June 2021. URL: http://dx.doi.org/10.1038/s41598-021-92881-x, doi:10.1038/s41598-021-92881-x. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-021-92881-x)

[5. (Elkins2002Structure) Patricia A. Elkins, Yen Sen Ho, Ward W. Smith, Cheryl A. Janson, Karla J. D’Alessio, Michael S. McQueney, Maxwell D. Cummings, and Anne M. Romanic. Structure of the c-terminally truncated human prommp9, a gelatin-binding matrix metalloproteinase. Acta Crystallographica Section D Biological Crystallography, 58(7):1182–1192, June 2002. URL: http://dx.doi.org/10.1107/s0907444902007849, doi:10.1107/s0907444902007849. This article has 120 citations.](https://doi.org/10.1107/s0907444902007849)

[6. (Xu2020Association) Tai Xu, Siming Zhang, Dongqin Qiu, Xiaoyuan Li, and Yuanlin Fan. Association between matrix metalloproteinase 9 polymorphisms and breast cancer risk: an updated meta-analysis and trial sequential analysis. Gene, 759:144972, October 2020. URL: http://dx.doi.org/10.1016/j.gene.2020.144972, doi:10.1016/j.gene.2020.144972. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2020.144972)

[7. (Rashid2023Novel) Zainab Ahmed Rashid and Sanaa K. Bardaweel. Novel matrix metalloproteinase-9 (mmp-9) inhibitors in cancer treatment. International Journal of Molecular Sciences, 24(15):12133, July 2023. URL: http://dx.doi.org/10.3390/ijms241512133, doi:10.3390/ijms241512133. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241512133)

[8. (Olson2000Characterization) Matthew W. Olson, M.Margarida Bernardo, Martin Pietila, David C. Gervasi, Marta Toth, Lakshmi P. Kotra, Irina Massova, Shahriar Mobashery, and Rafael Fridman. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Journal of Biological Chemistry, 275(4):2661–2668, January 2000. URL: http://dx.doi.org/10.1074/jbc.275.4.2661, doi:10.1074/jbc.275.4.2661. This article has 121 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.275.4.2661)

[9. (Vafadari2016MMP‐9) Behnam Vafadari, Ahmad Salamian, and Leszek Kaczmarek. <scp>mmp</scp>‐9 in translation: from molecule to brain physiology, pathology, and therapy. Journal of Neurochemistry, 139(S2):91–114, March 2016. URL: http://dx.doi.org/10.1111/jnc.13415, doi:10.1111/jnc.13415. This article has 279 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/jnc.13415)

[10. (Rowsell2002Crystal) Siân Rowsell, Paul Hawtin, Claire A. Minshull, Holly Jepson, Sarah M.V. Brockbank, Derek G. Barratt, Anthony M. Slater, William L. McPheat, David Waterson, Adriano M. Henney, and Richard A. Pauptit. Crystal structure of human mmp9 in complex with a reverse hydroxamate inhibitor. Journal of Molecular Biology, 319(1):173–181, May 2002. URL: http://dx.doi.org/10.1016/S0022-2836(02)00262-0, doi:10.1016/s0022-2836(02)00262-0. This article has 291 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/S0022-2836(02)00262-0)

[11. (Wang2021MMP1) Tianyu Wang, Yuanyuan Zhang, Jianhao Bai, Yawen Xue, and Qing Peng. Mmp1 and mmp9 are potential prognostic biomarkers and targets for uveal melanoma. BMC Cancer, September 2021. URL: http://dx.doi.org/10.1186/s12885-021-08788-3, doi:10.1186/s12885-021-08788-3. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-021-08788-3)

[12. (Stellas2010Monoclonal) Dimitris Stellas, Avraam El Hamidieh, and Evangelia Patsavoudi. Monoclonal antibody 4c5 prevents activation of mmp2 and mmp9 by disrupting their interaction with extracellular hsp90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biology, July 2010. URL: http://dx.doi.org/10.1186/1471-2121-11-51, doi:10.1186/1471-2121-11-51. This article has 106 citations.](https://doi.org/10.1186/1471-2121-11-51)

[13. (Vandooren2013Biochemistry) Jennifer Vandooren, Philippe E. Van den Steen, and Ghislain Opdenakker. Biochemistry and molecular biology of gelatinase b or matrix metalloproteinase-9 (mmp-9): the next decade. Critical Reviews in Biochemistry and Molecular Biology, 48(3):222–272, April 2013. URL: http://dx.doi.org/10.3109/10409238.2013.770819, doi:10.3109/10409238.2013.770819. This article has 579 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/10409238.2013.770819)

[14. (Cheng2022Landscape) Tianyi Cheng, Peiying Chen, Jingyi Chen, Yingtong Deng, and Chen Huang. Landscape analysis of matrix metalloproteinases unveils key prognostic markers for patients with breast cancer. Frontiers in Genetics, January 2022. URL: http://dx.doi.org/10.3389/fgene.2021.809600, doi:10.3389/fgene.2021.809600. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2021.809600)

[15. (Farina2014Gelatinase) Antonietta Farina and Andrew Mackay. Gelatinase b/mmp-9 in tumour pathogenesis and progression. Cancers, 6(1):240–296, January 2014. URL: http://dx.doi.org/10.3390/cancers6010240, doi:10.3390/cancers6010240. This article has 155 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers6010240)